Abstract Body

Background: The functional capacity of renal tubules to reabsorb phosphate declines with age. The extent to which this is affected by tenofovir (TDF) exposure and its effects on bone are unknown. We investigated the association between phosphate reabsorption, age, TDF exposure and bone mineral density (BMD).

Methods: Male HIV-positive patients taking part in a prospective study to evaluate BMD were analysed for phosphate wasting using maximum threshold for phosphate reabsorption (TmPO4/GFR), derived by the Kenny and Glen algorithm. Bone resorption was assessed by serum carboxy-terminal collagen crosslinks (CTX), bone formation by type 1 procollagen (P1NP), and BMD by dual-energy x-ray absorptiometry. Correlation coefficients and linear regression were used to evaluate relationships between variables.

Results: 411 men (mean age 47.4 [SD 9.8] years, 94.3% white, 92.9% MSM, diagnosed for a median 9.6 [IQR 5.0-15.5] years, 69.4% on TDF) were included. TmPO4/GFR correlated with age (r2=-0.2, p=0.006), parathyroid hormone (PTH) concentrations (r2=0.1, p=0.02) and, in those over 50 years, with lumbar spine BMD (r2=-0.2, p=0.02). Among subjects aged 30-70 years on antiretroviral therapy, TmPO4/GFR did not differ among those exposed versus those not exposed to TDF (Figure). In multivariable analysis, TmPO4/GFR remained associated with older age (β -0.03 [95% CI -0.05, -0.01] per 10 years, p=0.003) and 25 (OH) vitamin D (β 0.001 [95% CI 0.0001, 0.002] p=0.03), while univariable associations with nadir CD4 cell count, prior AIDS, HIV viral load, TDF and protease inhibitor exposure, P1NP and PTH were no longer significant after adjustment. TmPO4/GFR was not associated with CTX (p=0.9), BMD spine (p=0.1), BMD total hip (p=0.5) or BMD femoral neck (p=0.5).

Conclusions: In HIV-positive men, reduced phosphate reabsorption was common. Similar to observations reported in the general population, TmPO4/GFR declined with age but was not significantly associated with TDF exposure, increased bone resorption, or lower BMD. Our results suggest that in patients stable on antiretroviral therapy, TmPO4/GFR may not be useful in identifying patients at increased risk of bone loss.

viewer?TAG_ACTION=SECURE_FILE_DOWNLOAD&V
Mean maximum threshold for phosphate reabsorption (TmPO4/GFR) according to tenofovir (TDF) exposure, stratified by age